$0.87
-0.03 (-3.33%)
Open$0.92
Previous Close$0.90
Day High$0.93
Day Low$0.87
52W High$2.46
52W Low$0.87
Volume—
Avg Volume121.6K
Market Cap14.93M
P/E Ratio—
EPS$-0.90
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,770.1% upside
Current
$0.87
$0.87
Target
$16.27
$16.27
$12.16
$16.27 avg
$21.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.84M | 5.24M | 3.86M |
| Net Income | -13,176,148 | -16,180,288 | -155,305 |
| Profit Margin | -343.0% | -325.8% | -4.0% |
| EBITDA | -13,962,239 | -18,098,140 | -205,551 |
| Free Cash Flow | — | — | -168,121 |
| Rev Growth | -26.7% | -26.7% | +19.6% |
| Debt/Equity | — | — | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |